[go: up one dir, main page]

MA53664A - Composés destinés au traitement de certaines leucémies - Google Patents

Composés destinés au traitement de certaines leucémies

Info

Publication number
MA53664A
MA53664A MA053664A MA53664A MA53664A MA 53664 A MA53664 A MA 53664A MA 053664 A MA053664 A MA 053664A MA 53664 A MA53664 A MA 53664A MA 53664 A MA53664 A MA 53664A
Authority
MA
Morocco
Prior art keywords
compounds
treatment
certain leukemia
leukemia
certain
Prior art date
Application number
MA053664A
Other languages
English (en)
Inventor
Randall Halcomb
Thorsten A Kirschberg
F Anthony Romero
Yingzi Xu
Original Assignee
Terns Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Inc filed Critical Terns Inc
Publication of MA53664A publication Critical patent/MA53664A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA053664A 2018-09-18 2019-09-17 Composés destinés au traitement de certaines leucémies MA53664A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862733029P 2018-09-18 2018-09-18
US201962816637P 2019-03-11 2019-03-11
US201962889929P 2019-08-21 2019-08-21

Publications (1)

Publication Number Publication Date
MA53664A true MA53664A (fr) 2022-05-04

Family

ID=69774840

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053664A MA53664A (fr) 2018-09-18 2019-09-17 Composés destinés au traitement de certaines leucémies

Country Status (19)

Country Link
US (4) US10889571B2 (fr)
EP (1) EP3852745A4 (fr)
JP (2) JP7611832B2 (fr)
KR (1) KR20210061377A (fr)
CN (3) CN115215838B (fr)
AU (2) AU2019342102B2 (fr)
BR (1) BR112021004051A2 (fr)
CA (1) CA3110576A1 (fr)
CL (1) CL2021000637A1 (fr)
CO (1) CO2021004704A2 (fr)
IL (2) IL281427B1 (fr)
MA (1) MA53664A (fr)
MX (2) MX2021003093A (fr)
NZ (1) NZ773110A (fr)
PE (1) PE20211644A1 (fr)
SG (1) SG11202102367TA (fr)
TW (1) TWI826525B (fr)
WO (1) WO2020061086A2 (fr)
ZA (1) ZA202101304B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211644A1 (es) 2018-09-18 2021-08-24 Terns Inc Compuestos para tratar ciertas leucemias
RS65335B1 (sr) 2018-10-05 2024-04-30 Annapurna Bio Inc Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
EP3938351A1 (fr) 2019-03-11 2022-01-19 InflaRx GmbH Composés bicycliques pipéridinyles fusionnés et composés apparentés en tant que modulateurs du récepteur c5a
EP3947369A4 (fr) * 2019-07-29 2022-10-05 Ascentage Pharma (Suzhou) Co., Ltd. Composés hétérocycliques utilisés en tant qu'inhibiteurs de bcr-abl
US12398127B2 (en) 2019-09-12 2025-08-26 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
EP4301357A4 (fr) * 2021-03-03 2025-01-22 Terns Pharmaceuticals, Inc. Composés agonistes bêta du récepteur de l'hormone thyroïdienne
CN116375650B (zh) * 2022-12-30 2025-08-05 浙江美诺华药物化学有限公司 一种替戈拉生中间体的制备方法
EP4568664A1 (fr) 2023-04-07 2025-06-18 Terns Pharmaceuticals, Inc. Association comprenant un agoniste thrbeta anda glp-1r destiné à être utilisé dans le traitement d'un trouble du foie ou d'une maladie cardiométabolique
US20250090530A1 (en) * 2023-08-31 2025-03-20 Terns Pharmaceuticals, Inc. Combinations for the treatment of cancer
WO2025226724A1 (fr) * 2024-04-23 2025-10-30 Terns Pharmaceuticals, Inc. Inhibiteurs de bcr-abl1 destinés à être utilisés dans le traitement du cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271390B1 (en) 1998-05-22 2001-08-07 Avanir Pharmaceuticals Suppression of the IgE-dependent allergic response by benzimidazole analogs
SE0003476D0 (sv) 2000-09-28 2000-09-28 Astrazeneca Ab Compounds
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
TW200716110A (en) * 2005-04-20 2007-05-01 Smithkline Beecham Corp Inhibitors of AKT activity
CN101553468A (zh) * 2006-10-18 2009-10-07 诺瓦提斯公司 有机化合物
AR063311A1 (es) * 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
GB0800035D0 (en) 2008-01-02 2008-02-13 Glaxo Group Ltd Compounds
WO2013033093A1 (fr) 2011-08-29 2013-03-07 Biocryst Pharmaceuticals, Inc. Composés hétérocycliques utilisables en tant qu'inhibiteurs des janus kinases
CN104302634B (zh) 2012-05-15 2017-02-08 诺华股份有限公司 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
EA026559B1 (ru) 2012-05-15 2017-04-28 Новартис Аг Соединения и композиции для ингибирования активности abl1, abl2 и bcr-abl1
HUE039138T2 (hu) 2012-05-15 2018-12-28 Novartis Ag Benzamidszármazékok ABL1, ABL2 és BCR-ABL1 aktivitás gátlására
TR201807207T4 (tr) 2012-06-11 2018-06-21 Ucb Biopharma Sprl Tnf-alfa modüle edici benzimidazol bileşikleri.
CN103113355B (zh) 2013-02-27 2014-08-13 无锡爱内特生物科技有限公司 一种Bcr/Abl酪氨酸激酶抑制剂及其制备方法和在治疗慢性粒细胞白血病中的应用
GB201401086D0 (en) * 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US9931342B2 (en) 2016-02-02 2018-04-03 Duke University Compositions and methods for the treatment of cancer
CN109790144A (zh) 2016-04-29 2019-05-21 爱仕达生物技术有限责任公司 新型杂环化合物作为酪氨酸激酶bcr-abl抑制剂
US11091462B2 (en) 2017-01-20 2021-08-17 Shenzhen Targetrx, Inc. (Hetero)arylamide compound for inhibiting protein kinase activity
CN110724139B (zh) 2017-01-20 2021-05-18 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的(杂)芳基酰胺类化合物
WO2018191146A1 (fr) * 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Inhibiteurs de rheb à base d'hétéroaryle et leurs utilisations
WO2019173761A1 (fr) 2018-03-09 2019-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Composé inhibiteur de tyrosine kinase c-abl, modes de réalisation, procédés de fabrication et d'utilisation associés
PE20211644A1 (es) 2018-09-18 2021-08-24 Terns Inc Compuestos para tratar ciertas leucemias
WO2022232318A1 (fr) 2021-04-27 2022-11-03 Merck Sharp & Dohme Corp. Inhibiteurs à petites molécules de mutant de kras g12c
WO2023051681A1 (fr) 2021-09-30 2023-04-06 江苏豪森药业集团有限公司 Composé cyclique fusionné à quatre chaînons, son procédé de préparation et son utilisation
AU2024249677A1 (en) 2023-03-30 2025-11-13 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Salt crystal form of quaternary fused ring compound, and preparation method therefor and use thereof
US20250090530A1 (en) 2023-08-31 2025-03-20 Terns Pharmaceuticals, Inc. Combinations for the treatment of cancer

Also Published As

Publication number Publication date
EP3852745A2 (fr) 2021-07-28
CL2021000637A1 (es) 2021-10-01
US20250276961A1 (en) 2025-09-04
US20200087283A1 (en) 2020-03-19
CO2021004704A2 (es) 2021-04-30
AU2019342102A1 (en) 2021-03-11
KR20210061377A (ko) 2021-05-27
JP7611832B2 (ja) 2025-01-10
US20240101536A1 (en) 2024-03-28
US20250243184A1 (en) 2025-07-31
WO2020061086A2 (fr) 2020-03-26
IL322515A (en) 2025-10-01
IL281427B1 (en) 2025-09-01
ZA202101304B (en) 2024-09-25
JP2025066704A (ja) 2025-04-23
TW202024037A (zh) 2020-07-01
WO2020061086A3 (fr) 2020-07-23
CN112770745B (zh) 2022-09-02
MX2021003093A (es) 2021-05-12
MX2023007714A (es) 2023-07-10
IL281427A (en) 2021-04-29
CN115448908B (zh) 2025-04-25
NZ773110A (en) 2024-11-29
PE20211644A1 (es) 2021-08-24
US12454524B2 (en) 2025-10-28
EP3852745A4 (fr) 2022-05-04
AU2024287115A1 (en) 2025-01-16
SG11202102367TA (en) 2021-04-29
CN115215838A (zh) 2022-10-21
CN112770745A (zh) 2021-05-07
TWI826525B (zh) 2023-12-21
AU2019342102B2 (en) 2024-10-03
CA3110576A1 (fr) 2020-03-26
US12240835B2 (en) 2025-03-04
US10889571B2 (en) 2021-01-12
BR112021004051A2 (pt) 2021-05-25
CN115215838B (zh) 2025-04-04
JP2022501429A (ja) 2022-01-06
CN115448908A (zh) 2022-12-09

Similar Documents

Publication Publication Date Title
EP3852745A4 (fr) Composés destinés au traitement de certaines leucémies
EP3836923A4 (fr) Composés pyrrolo-dipyridine
EP3956033A4 (fr) Composés bicycliques
MA52948A (fr) Composés
EP3781156A4 (fr) Composés spirocycliques
MA51669A (fr) Composés
MA46524A (fr) Composés de biphényl-sulfonamide destinés au traitement de néphropathies
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
IL285771A (en) Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
EA201791208A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
MA53003A (fr) Composés
EP3340971A4 (fr) Méthodes de traitement de syndrome de lennox-gastaut à l'aide de fenfluramine
EP3853210A4 (fr) Composés antibactériens
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
MA51738A (fr) Composés pour le traitement de la douleur
EP3349793A4 (fr) Anti-s100a8 pour le traitement de la leucémie
EP4077318A4 (fr) Composés
MA52946A (fr) Composés
EP3416645A4 (fr) Composés pour le traitement du paludisme
EP3016944A4 (fr) Composés destinés au traitement de la mucosviscidose
IL282311A (en) Use of reboxetine to treat narcolepsy
EP3852816A4 (fr) Méthodes de traitement de cancer
MA45552A (fr) Compositions destinées au traitement de l'amylose
EP3873528A4 (fr) Traitement de rasopathie
IT201600121617A1 (it) Composizione per il trattamento del reflusso gastroesofageo